C occidioides immitis and C. posadasii, the etiologic agents of coccidioidomycosis, also known as Valley fever, are environmental filamentous fungi with distinct geographic ranges in the western United States, northern Mexico, and parts of Central and South America (1,2). In 2015, C. immitis was discovered in Washington, USA (3). That discovery highlighted the importance of using molecular detection methods (3,4) and enhanced efforts to study Coccidioides spp. outside traditionally identified endemic areas. Finding that Coccidioides might exist outside its previously established endemic regions supports the hypothesis that the geographic range of this pathogen may be changing (5).In recent years, genomic analyses of this pathogenic genus uncovered strong phylogeographic structure and delineated populations associated with specific geographic regions, findings that expand previous work based on immunological studies (6) and molecular studies using traditional, less-discerning methods (7). C. immitis is found primarily in California and Washington, C. posadasii in Arizona, Texas, Mexico, and Central and South America (8). Within species, population structure has been characterized, separating the Washington isolates from other C. immitis strains (3,9) and dividing C. posadasii into several differentiated phylogeographic clades (10), including the Arizona and Texas/Mexico/South America (TX/ MX/SA) clades, and a more recently delimited Guatemala/Venezuela clade (11). Although no phenotypic distinction between these groups has been associated with disease outcome, the genetic differences and population structures among these clades represent considerable assets for molecular epidemiology and enable tracking of the origins of infections.Coccidioides spp. can infect several species of mammals, including humans. Both immunocompromised and immunocompetent persons can develop coccidioidomycosis by inhaling airborne propagules from disturbed soil (2). In human hosts, symptoms range from inconsequential to self-limited and often protracted respiratory illness to chronic pulmonary disorders and, in rare cases, disseminated systemic infections (12,13). In the United States, >10,000 new cases/year have been reported to public health authorities in recent years, mainly in Arizona and California (13,14). Those states are also thought to be the source of most travel-related infections, as confirmed by the results of enhanced surveillance from 2016 describing clinical and epidemiologic characteristics of reported cases from 14 coccidioidomycosis nonendemic states (12). In that study, most patients had either traveled to coccidioidomycosis-endemic regions